Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Study Evaluating AZR-MD-001 in Patients With Meibomian Gland Dysfunction and Evaporative Dry Eye Disease (DED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, 18 years of age or older~* Best-corrected visual acuity (BCVA) of 20/40 or better (Snellen equivalent), using the logarithm of the minimum angle of resolution (LogMAR) in each eye~* Evidence of meibomian gland obstruction~* Reported dry eye signs and symptoms within the past 3 months~Exclusion Criteria:~* Uncontrolled ocular disease (except for MGD and dry eye disease/keratoconjunctivitis sicca) or uncontrolled systemic disease~* Glaucoma, ocular hypertension, or intraocular pressure (IOP) in either eye at screening ≥24 mm Hg or has planned insertion/removal of glaucoma filtration shunts/devices during the study~* Corneal abnormality or disorder that impacts normal spreading of the tear film or corneal integrity~* BCVA worse than 20/40 in either eye~* Current use of punctal plugs, anticipated insertion during the study, or a history of punctal cautery in either eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AZR-MD-001 Low Dose (Type: EXPERIMENTAL): AZR-MD-001 Low Dose will be dosed up to once daily.
- AZR-MD-001 Mid Dose (Type: EXPERIMENTAL): AZR-MD-001 Mid Dose will be dosed up to once daily.
- AZR-MD-001 High Dose (Type: EXPERIMENTAL): AZR-MD-001 High Dose will be dosed up to once daily.
- AZR-MD-001 Vehicle (Type: SHAM_COMPARATOR): AZR-MD-001 Vehicle will be dosed up to once daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).